Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review

July 2021 | 64 pages | ID: L4AC4EF7847EN
GlobalData

Abstracts

Lupin Ltd (LUPIN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Lupin Ltd (Lupin) develops and manufactures generic and branded formulations, biotechnology products and active pharmaceutical ingredients (APIs). It has expertise in the areas of cardiovascular, asthma, diabetology, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drugs (NSAIDs), anti-TB and cephalosporins. The company undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation. Lupin develops value-added generic pharmaceuticals based on its platform technologies. The company along with its subsidiaries has manufacturing facilities in India, the US, Mexico and Brazil. Lupin is headquartered in Mumbai, Maharashtra, India.

Lupin Ltd Key Recent Developments

Jun 07,2021: Lupin launches digital asthma educator platform
Jun 03,2021: Lupin: Company's entry into the digital healthcare space with a focus to provide a digital therapeutics platform for doctors and patients in India
Apr 20,2021: Incorporation of wholly owned subsidiary in the USA under the name Lupin Oncology
Jan 29,2021: Lupin announces appointment of Mr. Mark D. McDade
Jan 28,2021: Lupin quarter III FY2021 results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Lupin Ltd - Key Facts
Lupin Ltd - Key Employees
Lupin Ltd - Key Employee Biographies
Lupin Ltd - Major Products and Services
Lupin Ltd - History
Lupin Ltd - Company Statement
Lupin Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Lupin Ltd - Business Description
Geographical Segment: India
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Others
Performance
Geographical Segment: The United States
Performance
R&D Overview
Lupin Ltd - Corporate Strategy
Lupin Ltd - SWOT Analysis
SWOT Analysis - Overview
Lupin Ltd - Strengths
Lupin Ltd - Weaknesses
Lupin Ltd - Opportunities
Lupin Ltd - Threats
Lupin Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Lupin Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 07, 2021: Lupin launches digital asthma educator platform
Jun 03, 2021: Lupin: Company's entry into the digital healthcare space with a focus to provide a digital therapeutics platform for doctors and patients in India
Apr 20, 2021: Incorporation of wholly owned subsidiary in the USA under the name Lupin Oncology
Jan 29, 2021: Lupin announces appointment of Mr. Mark D. McDade
Jan 28, 2021: Lupin quarter III FY2021 results
Nov 10, 2020: Lupin announces appointment of Mr. Robert Funsten as an independent director
Nov 09, 2020: U.S.FDA inspection of Lupin’s Somerset (NJ, US) facility
Nov 04, 2020: Lupin quarter II FY2021 results
Aug 12, 2020: Mr. K.B.S. Anand and Dr. Punita Kumar-Sinha join Lupin Board as Independent Directors
Aug 12, 2020: LUPIN : Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Lupin Ltd, Key Facts
Lupin Ltd, Key Employees
Lupin Ltd, Key Employee Biographies
Lupin Ltd, Major Products and Services
Lupin Ltd, History
Lupin Ltd, Other Locations
Lupin Ltd, Subsidiaries
Lupin Ltd, Joint Venture
Lupin Ltd, Key Competitors
Lupin Ltd, Ratios based on current share price
Lupin Ltd, Annual Ratios
Lupin Ltd, Annual Ratios (Cont...1)
Lupin Ltd, Annual Ratios (Cont...2)
Lupin Ltd, Interim Ratios
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Lupin Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Lupin Ltd, Performance Chart (2017 - 2021)
Lupin Ltd, Ratio Charts
Lupin Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Lupin Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021